Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spyros Papapetropoulos

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
CNS Neuroscience & Therapeutics|November 11, 2011
Patient diaries as a clinical endpoint in Parkinson's disease clinical trialsSpyridon Spyros Papapetropoulos
Headache|July 16, 2013
Biomarkers associated with migraine and their potential role in migraine managementPaul Durham, Spyros Papapetropoulos
Digital Biomarkers|February 26, 2020
The First Frontier: Digital Biomarkers for Neurodegenerative DisordersE Ray Dorsey, Spyros Papapetropoulos, Mulin Xiong, et al.
BMC Neurology|July 3, 2015
Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraineAndrew M Blumenfeld, Sheena K Aurora, Karen Laranjo, et al.
Frontiers in Neurology|June 28, 2019
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker SelectionSpyros Papapetropoulos, Margaret S Lee, Stacey Boyer, et al.
Neuro-Degenerative Diseases|November 20, 2018
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral AdministrationSpyros Papapetropoulos, Wenlei Liu, Sridhar Duvvuri, et al.
Journal of Neurology|November 8, 2012
Psychiatric comorbidities of episodic and chronic migraineDawn C Buse, Stephen D Silberstein, Aubrey N Manack, et al.
Clinical Pharmacology in Drug Development|September 27, 2025
The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric DiseasePaul Rolan, Elizabeth Doolin, Dharam Paul, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|August 31, 2014
Post-stroke spasticity: predictors of early development and considerations for therapeutic interventionJörg Wissel, Molly Verrier, David M Simpson, et al.
Psychiatry Research|February 15, 2025
A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL studySpyros Papapetropoulos, Elizabeth Doolin, Michael Odontiadis, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
CNS Neuroscience & Therapeutics|November 11, 2011
Patient diaries as a clinical endpoint in Parkinson's disease clinical trialsSpyridon Spyros Papapetropoulos
Headache|July 16, 2013
Biomarkers associated with migraine and their potential role in migraine managementPaul Durham, Spyros Papapetropoulos
Digital Biomarkers|February 26, 2020
The First Frontier: Digital Biomarkers for Neurodegenerative DisordersE Ray Dorsey, Spyros Papapetropoulos, Mulin Xiong, et al.
BMC Neurology|July 3, 2015
Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraineAndrew M Blumenfeld, Sheena K Aurora, Karen Laranjo, et al.
Frontiers in Neurology|June 28, 2019
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker SelectionSpyros Papapetropoulos, Margaret S Lee, Stacey Boyer, et al.
Neuro-Degenerative Diseases|November 20, 2018
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral AdministrationSpyros Papapetropoulos, Wenlei Liu, Sridhar Duvvuri, et al.
Journal of Neurology|November 8, 2012
Psychiatric comorbidities of episodic and chronic migraineDawn C Buse, Stephen D Silberstein, Aubrey N Manack, et al.
Clinical Pharmacology in Drug Development|September 27, 2025
The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric DiseasePaul Rolan, Elizabeth Doolin, Dharam Paul, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|August 31, 2014
Post-stroke spasticity: predictors of early development and considerations for therapeutic interventionJörg Wissel, Molly Verrier, David M Simpson, et al.
Psychiatry Research|February 15, 2025
A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) - The PREVAIL studySpyros Papapetropoulos, Elizabeth Doolin, Michael Odontiadis, et al.
Pageof 3